PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients-Reference-Cited by-同舟云学术

PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients

Published:2015-09 Issue:3 Volume:63 Page:651-660
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Han Tao,Xiang Dai-Min,Sun Wen,Liu Na,Sun Huan-Lin,Wen Wen,Shen Wei-Feng,Wang Ruo-Yu,Chen Cheng,Wang Xue,Cheng Zhuo,Li Heng-Yu,Wu Meng-Chao,Cong Wen-Ming,Feng Gen-Sheng,Ding Jin,Wang Hong-Yang

Publisher

Elsevier BV

Subject

Hepatology

Reference50 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Cancer statistics;Siegel;CA Cancer J Clin,2012

3. Hepatocellular carcinoma: an epidemiologic view;El-Serag;J Clin Gastroenterol,2002

4. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

5. The hallmarks of cancer;Hanahan;Cell,2000

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases;Acta Pharmaceutica Sinica B;2024-08

2. Hepatic protein tyrosine phosphatase Shp2 disruption mitigates the adverse effects of ethanol in the liver by modulating oxidative stress and ERK signaling;Life Sciences;2024-03

3. Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease;Current Drug Targets;2024-02

4. Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect;Physical Chemistry Chemical Physics;2024

5. TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway;Journal of Gynecologic Oncology;2024